HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Toru Kita Selected Research

saiboku-to

1/2005Suppressive mechanisms of Sairei-to on mesangial matrix expansion in rat mesangioproliferative glomerulonephritis.
9/2004Suppressive effects of Sairei-to on mesangial proliferation in a rat model of glomerulonephritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Toru Kita Research Topics

Disease

37Atherosclerosis
11/2018 - 05/2002
24Myocardial Infarction
09/2017 - 01/2003
22Coronary Artery Disease (Coronary Atherosclerosis)
06/2022 - 01/2003
21Heart Failure
01/2013 - 11/2003
18Glomerulonephritis
01/2016 - 09/2003
16Hypercholesterolemia
04/2012 - 12/2002
15Hypertension (High Blood Pressure)
02/2021 - 01/2003
15Stroke (Strokes)
10/2015 - 11/2005
12Thrombosis (Thrombus)
06/2015 - 07/2003
12Hypertrophy
03/2010 - 05/2003
11Atherosclerotic Plaque (Atheroma)
12/2012 - 02/2004
10Acute Coronary Syndrome
09/2017 - 12/2004
10Hemorrhage
08/2014 - 02/2005
9Cardiovascular Diseases (Cardiovascular Disease)
10/2015 - 02/2004
8Coronary Disease (Coronary Heart Disease)
02/2021 - 12/2002
8Diabetic Nephropathies (Diabetic Nephropathy)
08/2015 - 04/2004
8Body Weight (Weight, Body)
03/2010 - 01/2003
7Inflammation (Inflammations)
03/2017 - 04/2007
6Type 2 Diabetes Mellitus (MODY)
10/2016 - 03/2002
6Diabetes Mellitus
01/2015 - 01/2004
6Metabolic Syndrome (Dysmetabolic Syndrome X)
03/2010 - 01/2003
6Obesity
03/2010 - 01/2003
5Neoplasms (Cancer)
01/2021 - 03/2004
5Alzheimer Disease (Alzheimer's Disease)
01/2014 - 06/2003
5Insulin Resistance
03/2010 - 03/2008
4Myocardial Ischemia (Ischemic Heart Diseases)
09/2017 - 01/2003
4Unstable Angina
09/2017 - 03/2007
4Cardiac Sudden Death (Sudden Cardiac Arrest)
02/2012 - 03/2007
4Rupture
09/2010 - 02/2004
4Hyperlipidemias (Hyperlipidemia)
01/2009 - 03/2002
4IGA Glomerulonephritis (IGA Nephropathy)
03/2007 - 08/2004
4Proteinuria
02/2007 - 03/2002
3Dyslipidemias (Dyslipidemia)
02/2021 - 06/2008
3Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
02/2021 - 01/2004
3Chronic Renal Insufficiency
01/2015 - 08/2009
3Chronic Kidney Failure (Chronic Renal Failure)
01/2015 - 01/2006
3Anemia
10/2011 - 06/2006
3Vascular Diseases (Vascular Disease)
01/2009 - 01/2004
3Vascular System Injuries
02/2008 - 03/2004
3Sarcoidosis (Schaumann Disease)
03/2007 - 07/2005
3Infections
03/2007 - 08/2003

Drug/Important Bio-Agent (IBA)

29LipidsIBA
02/2021 - 05/2002
21oxidized low density lipoproteinIBA
02/2021 - 03/2002
18CholesterolIBA
06/2014 - 03/2002
14Proteins (Proteins, Gene)FDA Link
01/2021 - 05/2003
11Biomarkers (Surrogate Marker)IBA
09/2017 - 11/2006
10Glucose (Dextrose)FDA LinkGeneric
01/2021 - 08/2006
9Apolipoproteins E (ApoE)IBA
12/2012 - 09/2004
9ApolipoproteinsIBA
09/2011 - 12/2005
9Simvastatin (Zocor)FDA LinkGeneric
03/2010 - 12/2002
9Triglycerides (Triacylglycerol)IBA
03/2010 - 01/2003
8HDL CholesterolIBA
02/2021 - 01/2003
8Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
06/2016 - 07/2008
7Class E Scavenger Receptors (Lectin Like Oxidized Low Density Lipoprotein Receptor 1)IBA
09/2010 - 07/2005
7LectinsIBA
09/2010 - 08/2005
6LDL CholesterolIBA
02/2021 - 01/2004
6Eicosapentaenoic AcidIBA
01/2012 - 07/2008
5MicroRNAs (MicroRNA)IBA
03/2017 - 08/2009
5omega-Chloroacetophenone (Mace)IBA
10/2015 - 08/2009
5Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
01/2015 - 02/2009
5Sirolimus (Rapamycin)FDA Link
04/2014 - 06/2005
5CytokinesIBA
11/2012 - 12/2002
5Pharmaceutical PreparationsIBA
09/2010 - 12/2008
5CollagenIBA
03/2010 - 05/2004
4Probucol (Lorelco)FDA Link
06/2022 - 12/2008
4LDL Lipoproteins (beta Lipoproteins)IBA
02/2021 - 01/2004
4Fatty Acids (Saturated Fatty Acids)IBA
01/2015 - 05/2010
4Peptides (Polypeptides)IBA
01/2014 - 12/2005
4C-Reactive ProteinIBA
09/2010 - 01/2006
4SaltsIBA
05/2010 - 11/2003
4Transcription Factors (Transcription Factor)IBA
03/2010 - 05/2003
4Chemokine CXCL16IBA
10/2009 - 02/2004
4Brain Natriuretic Peptide (Natrecor)FDA Link
02/2009 - 12/2004
4LDL Receptors (LDL Receptor)IBA
10/2008 - 01/2004
4Lipoproteins (Lipoprotein)IBA
06/2008 - 03/2002
4Troponin T (Troponin T1)IBA
05/2007 - 12/2004
4Immunoglobulin A (IgA)IBA
03/2007 - 09/2003
4FibrinIBA
03/2007 - 07/2002
3AntioxidantsIBA
02/2021 - 06/2007
3nardilysinIBA
01/2021 - 01/2014
3AntigensIBA
09/2017 - 12/2002
3MetalsIBA
04/2014 - 09/2008
3Amyloid beta-PeptidesIBA
01/2014 - 12/2005
3thienopyridineIBA
06/2012 - 02/2009
3Monoclonal AntibodiesIBA
03/2011 - 01/2003
3propagermanium (Ge 132)IBA
03/2010 - 09/2007
3Phenylephrine (Neo-Synephrine)FDA LinkGeneric
03/2010 - 09/2004
3Histone Acetyltransferases (Histone Acetyltransferase)IBA
03/2010 - 02/2006
3Superoxide DismutaseIBA
05/2009 - 09/2004
3Cell Surface ReceptorsIBA
10/2008 - 07/2007
3Immunoglobulin G (IgG)IBA
10/2008 - 01/2003
3DNA (Deoxyribonucleic Acid)IBA
04/2008 - 02/2006
3Transforming Growth Factor beta (TGF-beta)IBA
06/2007 - 02/2006
3Scavenger Receptors (Scavenger Receptor)IBA
04/2007 - 07/2002

Therapy/Procedure

27Therapeutics
02/2021 - 12/2002
18Percutaneous Coronary Intervention
06/2015 - 06/2005
16Stents
01/2015 - 12/2004
10Coronary Artery Bypass (Coronary Artery Bypass Surgery)
01/2013 - 03/2007
6Secondary Prevention
02/2021 - 12/2002
3Operative Surgical Procedures
08/2014 - 04/2012